Genmab AS ADR (GMAB)

Currency in USD
50.60
-0.75(-1.46%)
Closed·
50.02-0.58(-1.15%)
·
GMAB is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
50.2451.72
52 wk Range
23.6259.97
Key Statistics
Prev. Close
51.35
Open
51.57
Day's Range
50.24-51.72
52 wk Range
23.62-59.97
Volume
2.9M
Average Vol. (3m)
4.15M
1-Year Change
66.1741%
Book Value / Share
105.98
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
GMAB Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
65.01
Upside
+28.48%
Members' Sentiments
Bearish
Bullish
ProTips
Trading at a high earnings multiple

Genmab AS ADR News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell

Analyst Ratings

10 Buy
2 Hold
0 Sell
Ratings:
12 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 65.01
(+28.48% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
Morgan Stanley
Hold56.00+10.67%57.00MaintainNov 13, 2026
Morgan Stanley
Hold57.00+12.65%42.00MaintainOct 30, 2026
Guggenheim
Buy80.00+58.10%58.00MaintainOct 30, 2026
H.C. Wainwright
Buy70.00+38.34%60.00MaintainOct 30, 2026
Truist Securities
Buy67.00+32.41%45.00MaintainOct 29, 2026

Genmab AS ADR SWOT Analysis


Market Valuation
Analysts suggest a potential undervaluation, with price targets ranging from $47 to DKK 2,400, highlighting the market's complex view of Genmab's prospects
Pipeline Potential
Explore Genmab's diverse pipeline, including promising candidates like Epkinly, GEN3014, and Rina S., poised to shape the company's future growth
Financial Crossroads
Despite strong financials and a 96.1% gross profit margin, Genmab's stock faces challenges as it prepares for the post-Darzalex era
Antibody Innovato
Genmab, a Danish biotech leader, leverages proprietary technology to develop cancer-fighting antibodies, boasting eight approved medicines and a robust pipeline
Read full SWOT analysis

Genmab AS ADR Earnings Call Summary for Q2/2026

  • Genmab raised FY 2026 revenue guidance to DKK 4.3-4.5B, up 19% YoY at midpoint; operating profit guidance lifted 7% to DKK 1.1-1.4B.
  • H1 revenue rose 25% YoY driven by EPKINLY (up 48% YoY) and DARZALEX; proprietary portfolio sales jumped 37% to DKK 396M.
  • Shares fell 1.88% to $28.71 despite raised guidance, as investors await key late-stage data readouts for EPKINLY, petosemtamab in Q4 2026-Q1 2027.
  • Operating profit increased 18% in H1 while OpEx guidance rose only 2%, reflecting disciplined spending despite investments in phase III trials and launches.
  • Management highlighted commercial momentum with EPKINLY expanding into community settings and 90%+ of key customers ordering for multiple sites.
Last Updated: 08/06/2026, 01:43 PM
Read Full Transcript
Genmab AS ADR investor slides for Q2/2026
Genmab H1 2026 slides
Last Update: Aug 06, 2026
See full investor slides

Earnings

Latest Release
Nov 05, 2026
EPS / Forecast
0.55 / 0.35
Revenue / Forecast
1.19B / 1.2B
EPS Revisions
Last 90 days

GMAB Income Statement

Compare GMAB to Peers and Sector

Metrics to compare
GMAB
Peers
Sector
Relationship
P/E Ratio
44.2x25.7x−0.2x
PEG Ratio
−0.830.840.00
Price / Book
5.1x5.1x2.6x
Price / LTM Sales
7.5x4.9x2.6x
Upside (Analyst Target)
28.5%10.6%77.0%
Fair Value Upside
Unlock10.5%13.7%Unlock

Genmab A/S, a biotechnology company, develops antibody-based products and product candidates for the treatment of cancer and other diseases in Denmark. The company markets EPKINLY and TEPKINLY for adult patients with relapsed or refractory (R/R) diffuse large b-cell lymphoma (DLBCL), large B-cell lymphoma, and follicular lymphoma (FL); and Tivdak for adult patients with recurrent/metastatic cervical cancer with disease progression on or after chemotherapy. It is also developing Epcoritamab for R/R DLBCL and FL, first line DLBCL and FL, B-cell non-Hodgkin lymphoma, R/R chronic lymphocytic leukemia and Richter’s syndrome, and aggressive mature B-cell neoplasms in pediatric patients; tisotumab vedotin for solid tumors; Acasunlimab for solid tumors and non-small cell lung cancer (NSCLC); Rinatabart Sesutecan for platinum resistant ovarian cancer and solid tumors; GEN1059, GEN1055, and GEN1057 for solid tumors; and GEN1286 for advanced solid tumors. In addition, the company offers DARZALEX/DARZALEX FASPRO for multiple myeloma (MM) and light-chain Amyloidosis; RYBREVANT for NSCLC; TECVAYLI and TALVEY for R/R MM; Kesimpta for Relapsing multiple sclerosis; and TEPEZZA for thyroid eye disease. Further, it is developing Amivantamab for recurrent/metastatic head and neck cancer, and advanced or metastatic colorectal cancer; Amlenetug for multiple system atrophy; Inclacumab for vaso-occulsive crises in sickle cell diseases; and Mim8 for hemophilia A. The company has a collaboration agreement with AbbVie Inc., Pfizer Inc., BioNTech SE, Johnson & Johnson, Medarex, Inc., Bristol Myers Squibb Corporation, Lundbeck A/S, Amgen Inc., Novo Nordisk A/S, and argenx. Genmab A/S was incorporated in 1998 and is headquartered in Copenhagen, Denmark.

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
22.62M35.73%1.14B
Other Institutional Investors
23.25M36.73%1.18B
Public Companies & Retail Investors
17.43M27.54%882.08M
Total
63.29M100.00%3.2B

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
BlackRock, Inc.6.81%4,313,065218,241
Orbis Investment Management Limited6.67%4,223,096213,689

People Also Watch

460.54
LITE
-13.94%
64.63
EXEL
-1.82%
180.35
ALAB
-14.77%
81.31
NBIS
-16.11%
88.91
ANT
-8.50%

FAQ

What Is the Genmab AS ADR (GMAB) Stock Price Today?

The Genmab AS ADR stock price today is 50.60 USD.

What Stock Exchange Does Genmab AS ADR Trade On?

Genmab AS ADR is listed and trades on the Nasdaq Stock Exchange.

What Is the Stock Symbol for Genmab AS ADR?

The stock symbol for Genmab AS ADR is "GMAB."

What Is the Genmab AS ADR Market Cap?

As of today, Genmab AS ADR market cap is 32.21B USD.

What Is Genmab AS ADR's Earnings Per Share (TTM)?

The Genmab AS ADR EPS (TTM) is 11.86.

When Is the Next Genmab AS ADR Earnings Date?

Genmab AS ADR will release its next earnings report on Feb 24, 2027.

From a Technical Analysis Perspective, Is GMAB a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Neutral.

How Many Times Has Genmab AS ADR Stock Split?

Genmab AS ADR has split 1 times.

How Many Employees Does Genmab AS ADR Have?

Genmab AS ADR has 3244 employees.

What is the current trading status of Genmab AS ADR (GMAB)?

As of Nov 22, 2026, Genmab AS ADR (GMAB) is trading at a price of 50.60 USD, with a previous close of 51.35 USD. The stock has fluctuated within a day range of 50.24 USD to 51.72 USD, while its 52-week range spans from 23.62 USD to 59.97 USD.

What Is Genmab AS ADR (GMAB) Price Target According to Analysts?

The average 12-month price target for Genmab AS ADR is 65.01 USD, with a high estimate of 80 USD and a low estimate of 48 USD. 10 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +28.48% Upside potential.

What Is the GMAB Premarket Price?

GMAB's last pre-market stock price is 51.53 USD. The pre-market share volume is 15,530.00, and the stock has decreased by 0.18, or 0.35%.

What Is the GMAB After Hours Price?

GMAB's last after hours stock price is 50.02 USD, the stock has decreased by -0.58, or -1.15%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.